Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Inviting leukemic cells to waltz with the devil

The BCR-ABL oncoprotein of chronic myeloid leukemia can be converted into an active killer of the malignant cell when allowed to enter the nucleus. Could this lead to a three-step strategy to improve molecular targeting in the treatment of leukemia (pages 228–234)?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A molecule of ATP (A) is normally bound to the tyrosine kinase domain (SH1) of the BCR-ABL fusion protein, rendering it constitutively activated.

Bob Crimi

References

  1. Nowell, P.C. & Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497–1497 (1960).

    Google Scholar 

  2. Deininger, M.W., Goldman, J.M. & Melo, J.V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343–3356 (2000).

    CAS  PubMed  Google Scholar 

  3. Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100–104 (1996).

    CAS  PubMed  Google Scholar 

  4. Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561–566 (1996).

    Article  CAS  Google Scholar 

  5. Deininger, M.W.N., Goldman, J.M., Lydon, N.B. & Melo, J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 90, 3691–3698 (1997).

    CAS  PubMed  Google Scholar 

  6. le Coutre, P. et al. In vivo eradication of human BCR/ABL positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91, 163–168 (1999).

    Article  CAS  Google Scholar 

  7. Vigneri, P. & Wang, J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nature Med. 7, 228–234 (2001).

    Article  CAS  Google Scholar 

  8. Wen, S.T., Jackson, P.K. & Van Etten, R.A. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 15, 1583–1595 (1996).

    Article  CAS  Google Scholar 

  9. Taagepera, S. et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA 95, 7457–7462 (1998).

    Article  CAS  Google Scholar 

  10. Lewis, J.M., Baskaran, R., Taagepera, S., Schwartz, M.A., & Wang, J.Y. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic- nuclear transport. Proc. Natl. Acad. Sci. USA 93, 15174–15179 (1996).

    Article  CAS  Google Scholar 

  11. Van Etten, R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell. Biol. 9, 179–186 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melo, J. Inviting leukemic cells to waltz with the devil. Nat Med 7, 156–157 (2001). https://doi.org/10.1038/84591

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/84591

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing